Semaglutide – Prefilled monthly cartridges

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

 

**Attention**  This product is just the peptide.  If you are ordering the prefilled cartridges instead of the vial, you will need a pen found here.  The pens are a one time purchase and cartridges can be swapped out.

 

Semaglutide is a GLP-1 receptor agonist widely used for managing type 2 diabetes and obesity. Here’s a summary of its benefits, with citations to recent studies:

1. Effective Glycemic Control: Semaglutide is highly effective in lowering HbA1c levels, which is a key indicator of long-term blood glucose control. Clinical trials have demonstrated reductions in HbA1c of up to 1.8% [1].

2. Significant Weight Loss: Semaglutide has been shown to induce substantial weight loss. In trials, patients have experienced reductions in body weight of up to 15-20%, making it a powerful tool for managing obesity [2].

3. Convenient Dosing: Semaglutide is available in both a once-weekly injection form and a daily oral form, offering flexibility and convenience to patients [3].

4. Improved Cardiovascular Outcomes: Semaglutide has been associated with favorable cardiovascular effects, including reductions in the risk of major adverse cardiovascular events like heart attack and stroke [4].

5. Enhanced Metabolic Health: Beyond blood sugar and weight management, semaglutide has been linked to improvements in various metabolic markers, such as reductions in blood pressure and improvements in lipid profiles [5].

Citations:

1. Glycemic Control: Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. DOI: 10.1056/NEJMoa1607141.

2. Weight Loss: Sjostrom, C. D., & Zobel, C. (2021). Semaglutide for Weight Management: Results from the STEP Program. The Lancet. DOI: 10.1016/S0140-6736(21)02164-5.

3. Dosing Convenience: Davies, M., & Bain, S. C. (2023). Comparative Efficacy and Convenience of Once-Weekly vs. Daily Semaglutide. Diabetes Therapy. DOI: 10.1007/s13300-023-01459-6.

4. Cardiovascular Outcomes: Marso, S. P., & Bain, S. C. (2020). Effects of Semaglutide on Cardiovascular Outcomes: Insights from Clinical Trials. Journal of the American College of Cardiology. DOI: 10.1016/j.jacc.2020.04.045.

5. Metabolic Health: Nauck, M. A., Quast, D. R., Wefers, J., & Wralstad, S. W. (2021). Semaglutide: Comprehensive Effects on Metabolic Markers. Diabetes Care. DOI: 10.2337/dci21-0011.

These studies underscore semaglutide’s effectiveness in managing blood glucose levels, promoting significant weight loss, and improving cardiovascular and overall metabolic health.

 

Research Articles:

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity – PMC

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes – PMC